newsfilter.io
Aug 14, 2026, 5:30 PM ETHealthcare

Precipio — Q2-2026 Earnings Summary

PRPOPRECIPIO INC
Source

Financial Performance

  • Revenue reached a quarterly record of $7.0 million, representing a 22% year-over-year increase from $5.7 million in Q2-2025 and a sequential increase from $6.7 million in Q1-2026.
  • Revenue composition included $6.1 million in pathology revenue (up from $6.0 million in Q1) and $0.9 million in product revenue (up from $0.66 million in Q1).
  • Adjusted EBITDA turned positive at $0.4 million, compared to a loss of $(0.2) million in Q1-2026 and a loss of $(0.1) million in Q2-2025.
  • The improvement in Adjusted EBITDA was driven by a $0.3 million increase in revenues and a $0.2 million decrease in stock-based compensation expense.
  • Cash flow from operations was $0.7 million in Q2-2026, resulting in a total cash balance exceeding $3 million at quarter-end, up from $1.1 million in Q2-2025.
  • GAAP Net Loss was $(0.2) million in Q2-2026, compared to a Net Income of $0.1 million in Q2-2025.
  • EBITDA (non-GAAP) was $0.0 million in Q2-2026, down from $0.4 million in Q2-2025.
  • Stock-based compensation expense was $0.8 million in Q2-2026, up from $0.4 million in Q2-2025.
  • Other significant expenses were $(0.4) million in Q2-2026, compared to $(0.9) million in Q2-2025.

Business Segments and Product Lines

  • Product revenues increased 21% from the previous high of $750,000 recorded in Q4-2025.
  • The company reported customer growth contributing to the record revenue quarter.

Management Commentary and Tone

  • CEO Ilan Danieli described Q2 operating performance as reflecting a "healthy recovery and continued momentum," noting that customer growth generated the first quarterly revenue surpassing $7 million in company history.
  • Management highlighted that the cash balance exceeding $3 million was achieved without a financing event, demonstrating operational strength.
  • The CEO expressed encouragement regarding progress and stated the company is well-positioned to build on this momentum.

Other Key Points

  • The company is a specialty cancer diagnostics firm focused on developing diagnostic products and services to reduce cancer misdiagnoses.
  • A shareholder call to discuss Q2-2026 performance is scheduled for August 17, 2026, at 5 PM ET, featuring management remarks and a moderated Q&A session.
  • The press release includes a reconciliation of Net Income, EBITDA, and Adjusted EBITDA for the second quarters of 2026 and 2025.
  • The company directs investors to its Form 10-Q filed on the same day for additional results.